[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649561":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":16,"locations":10,"responsibleParty":22,"collaborators":10,"id":24,"slug":25,"hasResults":26,"nctId":27,"briefTitle":28,"officialTitle":29,"acronym":10,"eligibilityCriteria":30,"healthyVolunteers":26,"sex":31,"minAge":32,"maxAge":33,"enrollmentInfo":34,"targetDuration":10,"studyType":37,"phases":10,"briefSummary":38,"conditions":39,"keywords":43,"overallStatus":48,"whyStopped":10,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":10},{"fullName":5,"class":6},"Novartis","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Secukinumab Cohort",null,"Adult participants diagnosed with axSpA, AS, and nr-axSpA for whom the treating physician prescribes treatment with secukinumab 150 mg subcutaneous as per approved label.",[13],{"name":14,"affiliation":14,"role":15},"Novartis Pharmaceuticals","STUDY_DIRECTOR",[17,21],{"name":14,"role":18,"phone":19,"phoneExt":10,"email":20},"CONTACT","+41613241111","novartis.email@novartis.com",{"name":14,"role":18,"phone":10,"phoneExt":10,"email":10},{"type":23,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100649561","a-study-to-assess-the-safety-of-subcutaneous-secukinumab-for-treatment-in-adult-indian-participants-with-axial-spondyloarthritis-axspa-ankylosing-spondylitis-as-and-non-radiographic-axial-spondyloarthritis-nr-axspa-100649561",false,"NCT07737730","A Study to Assess the Safety of Subcutaneous Secukinumab for Treatment in Adult Indian Participants With Axial Spondyloarthritis (axSpA), Ankylosing Spondylitis (AS), and Non-Radiographic Axial Spondyloarthritis (nr-axSpA)","A Prospective, Observational, Multicentre Study to Assess the Safety of Subcutaneous Secukinumab 150 mg Solution for Treatment in Adult Indian Participants With Axial Spondyloarthritis (axSpA), Ankylosing Spondylitis (AS), and Non-Radiographic Axial Spondyloarthritis (nr-axSpA) Over a Period of 16 Weeks","Inclusion criteria:\n\n1. Participant or his\u002Fher legally acceptable representative (LAR) who are willing to voluntarily provide signed informed consent for participation in the study.\n2. Adult male or female participants (≥18 years) diagnosed with axSpA, AS, and nr-axSpA.\n\nExclusion criteria:\n\n1. Participants who meet any contraindication outlined in the current Prescribing Information (PI)\u002FPackage Insert for secukinumab at the time of screening.\n2. Pregnant or lactating women.\n3. Any surgical and\u002For medical condition, which in the opinion of the treating physician, may place the participant at higher risk of his\u002Fher participation in the study, or is likely to prevent the participant from complying with the requirements of the study or completing the study.","ALL","18 Years","100 Years",{"count":35,"type":36},60,"ESTIMATED","OBSERVATIONAL","The aim of this study is to assess the safety of secukinumab in Indian adult participants with axSpA, AS, and nr-axSpA over a 16-week treatment period. The present study is being undertaken to fulfill the Post Marketing Surveillance (PMS) mandate by the Health Authority (HA) to evaluate the safety of secukinumab solution for injection administered subcutaneously in a pre-filled pen in the indicated population under real-world clinical practice conditions.",[40,41,42],"Axial Spondyloarthritis","Ankylosing Spondylitis","Non-Radiographic Axial Spondyloarthritis",[44,45,42,46,47],"Axial Spondyloarthritis,","Ankylosing Spondylitis,","Secukinumab","Quality of Life","NOT_YET_RECRUITING","2026-07-27",{"date":51,"type":52},"2026-07-30","ACTUAL",{"date":54,"type":36},"2026-09-30",{"date":56,"type":36},"2027-04-30",{"name":14,"class":6}]